These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8407122)

  • 21. Tissue plasminogen activator as a biochemical adjuvant in vitrectomy for proliferative diabetic vitreoretinopathy.
    Hesse L; Chofflet J; Kroll P
    Ger J Ophthalmol; 1995 Nov; 4(6):323-7. PubMed ID: 8751095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reasons for and management of postvitrectomy vitreous hemorrhage in proliferative diabetic retinopathy.
    Yan H; Cui J; Lu Y; Yu J; Chen S; Xu Y
    Curr Eye Res; 2010 Apr; 35(4):308-13. PubMed ID: 20373898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapeutic and prophylactic application of TPA (recombinant tissue plasminogen activator) into the anterior chamber of the eye].
    Rehfeldt K; Höh H
    Ophthalmologe; 1999 Sep; 96(9):587-93. PubMed ID: 10501987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Vitreous hemorrhage after vitrectomy in diabetic retinopathy and tissue plasminogen activator].
    Asensio Sánchez VM; Pérez Flández FJ; Carlos Bejarano J; Fernández Concellón L
    Arch Soc Esp Oftalmol; 2002 Jan; 77(1):7-12. PubMed ID: 11813114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-dose tissue plasminogen activator in the management of anterior chamber fibrin formation.
    Georgiadis N; Boboridis K; Halvatzis N; Ziakas N; Moschou V
    J Cataract Refract Surg; 2003 Apr; 29(4):729-32. PubMed ID: 12686240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tissue plasminogen activator for the treatment of postoperative intraocular fibrinous membranes following cataract surgery.
    Schmitz K; Greite JH; Bartenschlager EM
    Ger J Ophthalmol; 1995 Mar; 4(2):75-9. PubMed ID: 7795512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment with tissue plasminogen activator (tPA) in risk patients with fibrin reactions after cataract operations].
    Heiligenhaus A; Schilling H; Schilling M; Mellin KB
    Ophthalmologe; 1996 Feb; 93(1):49-53. PubMed ID: 8867161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant tissue plasminogen activator in cases with fibrin formation after cataract surgery: a prospective randomised multicentre study.
    Heiligenhaus A; Steinmetz B; Lapuente R; Krallmann P; Althaus C; Steinkamp WK; Dick B
    Br J Ophthalmol; 1998 Jul; 82(7):810-5. PubMed ID: 9924378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intracameral tissue plasminogen activator to treat severe fibrinous effusion after cataract surgery.
    Wedrich A; Menapace R; Ries E; Polzer I
    J Cataract Refract Surg; 1997; 23(6):873-7. PubMed ID: 9292671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of intracameral fibrinous membranes with tissue plasminogen activator.
    Erol N; Ozer A; Topbas S; Yildirim N; Yurdakul S
    Ophthalmic Surg Lasers Imaging; 2003; 34(6):451-6. PubMed ID: 14620747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sonothrombolysis for intraocular fibrin formation in an animal model.
    Yamashita T; Ohtsuka H; Arimura N; Sonoda S; Kato C; Ushimaru K; Hara N; Tachibana K; Sakamoto T
    Ultrasound Med Biol; 2009 Nov; 35(11):1845-53. PubMed ID: 19699025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peripheral retinal cryotherapy for postvitrectomy diabetic vitreous hemorrhage in phakic eyes.
    Neely KA; Scroggs MW; McCuen BW
    Am J Ophthalmol; 1998 Jul; 126(1):82-90. PubMed ID: 9683153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of postcataract fibrinous membranes with tissue plasminogen activator.
    Moon J; Chung S; Myong Y; Chung S; Park C; Baek N; Rhee S
    Ophthalmology; 1992 Aug; 99(8):1256-9. PubMed ID: 1513579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-dose intraocular tissue plasminogen activator treatment for traumatic total hyphema, postcataract, and penetrating keratoplasty fibrinous membranes.
    Starck T; Hopp L; Held KS; Marouf LM; Yee RW
    J Cataract Refract Surg; 1995 Mar; 21(2):219-24. PubMed ID: 7791066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complications of tissue plasminogen activator therapy after vitrectomy for diabetes.
    Dabbs CK; Aaberg TM; Aguilar HE; Sternberg P; Meredith TA; Ward AR
    Am J Ophthalmol; 1990 Oct; 110(4):354-60. PubMed ID: 2121038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of experimental vitreous hemorrhage with tissue plasminogen activator.
    Min WK; Kim YB; Lee KM
    Korean J Ophthalmol; 1990 Jun; 4(1):12-5. PubMed ID: 2120486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of post-vitrectomy persistent vitreous hemorrhage in pseudophakic eyes.
    Landers MB; Perraki AD
    Am J Ophthalmol; 2003 Dec; 136(6):989-93. PubMed ID: 14644207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of tissue plasminogen activator for intraocular fibrinolysis in dogs.
    Gerding PA; Essex-Sorlie D; Vasaune S; Yack R
    Am J Vet Res; 1992 Jun; 53(6):894-6. PubMed ID: 1626779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Tissue plasminogen activator in treatment of fibrinous membranes after cataract surgery].
    Oficjalska-Młyńczak J; Marek J; Zajac-Pytrus H; Nizankowska MH; Koziorowska M
    Klin Oczna; 1996; 98(6):423-5. PubMed ID: 9340414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outpatient fluid-air exchange for severe postvitrectomy diabetic vitreous hemorrhage. Long-term results and complications.
    Han DP; Murphy ML; Mieler WF; Abrams GW
    Retina; 1991; 11(3):309-14. PubMed ID: 1961989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.